Cargando…

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy in fit patients, but there is limited evidence regarding the optimal treatment of patients after r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Dena R., Munir, Talha, Hockaday, Anna, Rawstron, Andy C., Collett, Laura, Oughton, Jamie B., Allsup, David, Bloor, Adrian, Phillips, David, Hillmen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028943/ https://www.ncbi.nlm.nih.gov/pubmed/27645620 http://dx.doi.org/10.1186/s13063-016-1581-0

Ejemplares similares

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
por: Collett, Laura, et al.
Publicado: (2017)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial
por: Munir, Talha, et al.
Publicado: (2022)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
por: Howard, Dena R., et al.
Publicado: (2021)

Experiences in the design and implementation of phase II trials in CLL
por: Cohen, Dena R, et al.
Publicado: (2011)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses
por: Rawstron, Andrew C., et al.
Publicado: (2022)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Mega-Trials
por: De Bono, David
Publicado: (1995)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
por: Appleby, Niamh, et al.
Publicado: (2019)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Tests of LM2 MicroMegas Modules on Cosmic Stand in Dubna
por: Demichev, Mikhail
Publicado: (2021)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022)

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study
por: van Oers, Marinus, et al.
Publicado: (2019)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Microvesicles in CLL: predictor of disease progression/relapse
por: Maiti, Guru P., et al.
Publicado: (2017)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
por: Linley, Adam J., et al.
Publicado: (2021)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Studies of MicroMegas Chamber for the New Small Wheel using Cosmic Muons
por: Klapdor-kleingrothaus, Thorwald, et al.
Publicado: (2016)

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0h3ev37rc7kuh1cqfaneqgmhi4